Can-Fite launches FDA/EMA-approved Phase 3 trial of Piclidenoson in psoriasis - BioTuesdays

Can-Fite launches FDA/EMA-approved Phase 3 trial of Piclidenoson in psoriasis - BioTuesdays

Can-Fite BioPharma (NYSE American:CANF) announced that it has initiated a pivotal Phase 3 study of its oral drug Piclidenoson for the treatment of psoriasis, with FDA- and EMA-approved protocol. According to Can-Fite, the study will enroll patients with moderate to severe plaque psoriasis. Patient enrolment will be initiated in Europe with the U.S. and Canada expected to follow. Patients will be treated with 3mg twice-daily oral Piclidenoson tab…